Keyphrases
COVID-19
100%
Travellers
84%
United States
55%
Remdesivir
55%
Ebola Virus Disease
49%
Pre-travel
35%
West Africa
32%
Healthcare Workers
24%
International Travellers
24%
Illness
23%
Baricitinib
22%
Rickettsia Parkeri
22%
Resource Utilization
22%
Treatment Effect
22%
Clinical Research
21%
Placebo
18%
High Risk
18%
Africa
17%
Lassa Fever
16%
International Travel
16%
Healthcare
16%
Travel-related Illness
16%
Medical Countermeasures
15%
SARS-CoV-2 Infection
14%
Travel Medicine
14%
Rocky Mountain Spotted Fever
14%
Treatment Trials
14%
Rickettsiosis
14%
Travel Health
14%
National Consortium
14%
Infectious Diseases
14%
Disease Severity
13%
Returning Travellers
13%
Government Hospitals
13%
GeoSentinel
13%
Patient Care
13%
Yellow Fever
12%
Yellow Fever Vaccine
12%
Japanese Encephalitis
12%
Hazard Ratio
12%
Clinical Progression
12%
Randomized Placebo-controlled Trial
12%
Clinical Features
11%
Hospitalized Adults
11%
Randomized Trial
11%
Drug Interactions
11%
Delta Variant
11%
Cryptococcal Infection
11%
Clinical Tropical Medicine
11%
Manufacturing Logistics
11%
Medicine and Dentistry
Disease
88%
Virus Infection
69%
Ebolavirus
55%
Infection
46%
Clinician
31%
Severe Acute Respiratory Syndrome Coronavirus 2
22%
Rickettsiosis
22%
Rickettsia parkeri
22%
Returning Traveler
22%
Randomized Controlled Trial
22%
Yellow Fever
20%
Diagnosis
19%
Lassa Fever
18%
COVID-19
18%
Travel Medicine
16%
Spotted Fever
15%
Patient Care
14%
Rocky Mountain Spotted Fever
13%
Consultation
13%
Japanese Encephalitis
13%
Drug Therapy
12%
Primary Health Care
12%
Clinical Research
12%
Rabies
11%
Personal Protective Equipment
11%
Jet Lag
11%
Permeability Barrier
11%
Immunocompromised Patient
11%
Pediatrics
11%
Cellulitis
11%
Health Care Cost
11%
Kidney Graft
11%
American Hemorrhagic Fever
11%
Immunomodulating Agent
11%
Nasopharyngeal Swab
11%
Yellow Fever Vaccine
11%
Meta-Analysis
11%
Lassa Virus
11%
Virus RNA
11%
Japanese Encephalitis Vaccine
11%
Hydrogen Sulfide
11%
Drug Interaction
11%
Demography
11%
Travel Related Disease
11%
Tropical Disease
11%
Lung
11%
Enzyme Linked Immunosorbent Assay
11%
Immunogenicity
11%
Booster Dose
11%
Amblyomma maculatum
9%